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Abstract. Clinical investigations (CIs) are carried out to demonstrate safety and 
efficacy of new Medical Devices (MDs). The presence of many stakeholders 
participating in CIs makes it necessary to develop a common standard language to 
achieve semantic interoperability among systems and organizations. In Italy the 
National Research Council is carrying out a project supported by Ministry of 
Health aiming to develop an information system (MEDIS) that manages MD 
clinical investigations. In order to develop a flexible and interoperable system, 
MEDIS design has been based on the application of HL7 (Health Level 7) v.3 
standards. This paper presents the results of the MEDIS design: the MD DAM 
based on HL7 RIM.  
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1. Introduction 
Innovation and development of new medical devices (MDs) are carried out establishing 
a body of evidence that demonstrates their safety and efficacy. Clinical investigations 
(CIs) are one of the most important methods of testing MD safety and performance on 
humans before its regulatory approval and commercialization. European directives >1@,
national laws as well as a body of international technical norms, regulate these complex 
procedures. These regulations tend to implement similar approaches, in order to 
monitor an increasing number and types of MDs commercialized in a global market. 
Unlike clinical trials on pharmaceuticals, there is no European registry that gathers 
information on MD clinical research yet, and only few countries have developed their 
own information system to monitor clinical investigations. Also the use of standardized 
clinical data is at its initial stage in the MD domain, while this is becoming a common 
practice in the field of pharmaceutical clinical trials, as evident in the development of 
CDISC standards [2] or in the models proposed by BRIDG [3] and caBIG [4]. 
However, a simple application of the standards proposed for pharmaceutical clinical 
research is not possible due to the great variety of MDs as well as differences in CI 
approval and commercialization procedures.  
Therefore, information sharing on MDs has to be based on the identification of a 
standard set of data able to describe MD characteristics and track them in interoperable 
information systems. The need of information sharing among National Competent 
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Authorities (NCAs) and CI proposers as well as among the different stakeholders 
participating in CIs, makes it necessary to develop a common standard language to 
achieve semantic interoperability among systems and organizations.  
In Europe the EUDAMED (European Database for Medical Devices) project is 
planning an information system with the aim to support Member States in the 
information exchange related to MD placed on the market. In Italy the National 
Research Council is carrying out a project supported by Ministry of Health aiming to 
develop an information system (MEDIS) that manages MD clinical investigations. The 
core of MEDIS is composed by a registry of clinical investigation data and content 
repository of documents submitted by the manufacturer to the NCA to obtain the 
approval for the clinical investigation start-up. Moreover, MEDIS supports 
manufacturers in the documentation submission process as well as the NCA evaluators 
in assessing the data received. It also manages the communication among the different 
stakeholders and collects the data produced during the whole lifecycle of CIs.  
In order to develop a flexible and interoperable system, MEDIS design and 
development have been based on the application of HL7 (Health Level 7) v.3 standards. 
This paper presents the results of the MEDIS design focusing in particular on the use of 
HL7 RIM [5] in the MD domain.  
2. The MEDIS System 
MEDIS is primary a registry that collects the data and documents during the whole 
lifecycle of a CI, from the phase of notification, i.e., the submission of regulatory data 
and documents to obtain the approval of CI start-up to the phase of collecting the final 
results of a CI. In particular MEDIS manages: (1) The acquisition of data and 
documents required by the national and European Directives to obtain the approval for 
the activation of a CI (notification phase), providing a CI proposer with an electronic 
submission form that guides him/her to the correct insertion of information; (2) 
Communication exchanges between CI proposer and NCA evaluators that manage the 
requests of further information for assessment aims as well as the updating of CI data 
and documents occurring both in evaluation and experimentation phases; (3) 
Communication exchange among the NCA evaluators that manages the assignments of 
roles as well as the agenda of the evaluation phase by means of a workflow of the 
activities carried out during the evaluation process performed by the NCA evaluators. 
Particular attention has been posed on issues related to data security and privacy. 
3. HL7
HL7 provides standards for the exchange, management and integration of electronic 
healthcare related data based on a conceptual model (Reference Information Model, 
RIM), an exchange model for clinical documents (CDA), clinical content management 
specifications (CCOW) and messaging exchange (Domain Message Information Model, 
DMIM). Such standards set the language, structure and data types required for 
seamless integration among different systems and organizations. RIM is the core of 
HL7 v.3; it represents a static model that covers both clinical data and administrative 
information in the healthcare context. Its abstract data model approach makes it 
possible to easily adapt it to other domains. Moreover, CDA standardization makes 
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HL7 particularly suitable for MEDIS requirements, as far as extraction and re-use of 
the information contained in the CI technical documents are concerned.  
HL7 RIM describes a health business process decomposing it into elementary 
descriptions, which model: a) the subject/object involved in the process, b) the role 
played by the subject/object, c) the aim, and d) the action performed or scheduled. This 
description is based on a speech act [6], represented by the 4thple <Entity, Role, 
Participation, Act>. Therefore, in the HL7 RIM data are represented in Entities (e.g., 
people places and things, nouns) related in Roles (relators) to other Entities, which 
interact in Acts (verbs) through their Participations (prepositions). Through 
ActRelationship it is possible to represent different associations, for instance a 
temporal, logical or structural order, composition, etc. Through RoleLink, it is possible 
to connect for example a physician with its belonging organization, relation between 
organizations, etc. This conceptual model makes it possible to describe data and their 
attributes as well as static procedural information that characterize a process.  
An example of the application of RIM to MEDIS stakeholders is described by the 
sentence “A MD manufacturing enterprise submits a notification through its legal re-
presentative” by mean of the following 4thples: <Organization, Proposer environment, 
Manufacturer, Notification> and <Person, Proposer, Legal representative, Notification>.
4. MEDIS Business Process 
The life cycle of a CI on MDs can be divided into three main sub-processes: (1) In the 
notification sub-process, the CI proposer sends the NCA the documentation composed 
by administrative documents (letter of designation of an authorized representative, 
signed statement, etc.) and technical documentation (clinical protocol, the risk analysis 
document, etc.); (2) In the evaluation sub-process, the NCA assigns the notification to 
an evaluation team, a medical and a technical evaluator, which can also benefit from an 
external specialized advisory board to assess special aspects of CI performance and 
MD safety requirements. This sub-process entails an administrative review that verifies 
the completeness and the consistency of documentation and a content review that 
assesses MD safety requirements as well as the scientific, clinical and ethical 
fulfillments of the clinical protocol; (3) If the CI is approved, in the investigation sub-
process, the proposer can start the clinical study. He/she also communicates with the 
NCA about amendments in the clinical protocol and/or reports adverse events. 
5. MEDIS Domain Analysis Model (DAM) 
The MEDIS DAM entails five Entities: Organization, Person, Committee, Document 
and Artifact (Figure 1). Organization, Person and Committee represent the stakeholders 
taking part in the CI lifecycle, each one playing a specific Role with precise intentions 
(Participation). For instance each Person can play either the Role of Proposer,
Evaluator, Performer or Patient. In particular the Role Proposer is associated with the 
Participations Legal representative (responsible for the notification submission and CI 
performance) and Contact person (responsible for the communication exchange with 
the NCA). Their Participation is connected with the whole process, i.e., the Notifying,
Evaluating and Investigating Acts. The Role Evaluator is linked to the Participations 
Notification supervisor, Medical evaluator and Technical evaluator involved in the 
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processes of assessment and CI monitoring (i.e., Acts: Evaluating process and 
Investigating process).
The Entity Document identifies the information exchanged during the whole CI 
lifecycle, associating each document type to its Role on the basis on its aim 
(Participation) in a specific Act. For instance the Role Notification has the function of 
participating as an Evaluation object in the whole CI process. Similarly the Role 
Technical document, such as clinical protocol, participates as an Activity plan sent by 
the Proposer in the Notifying process, assessed by the Evaluation team in the 
Evaluating process, and followed by the Performer in the Investigating process. Note 
that HL7 RIM describes the subject and the object of an act through two different 
4thples. For this reason it is necessary to develop system constrains to associate these 
classes to each Act. The Role Update describes the set of documents composing the 
Dossier together with those contained in the Notification, modeling the information 
exchange necessary to manage changes occurring during the whole CI process (for 
example different versions of a document, protocol amendments, etc.). 
Figure 1. MEDIS domain analysis model 
Figure 2 shows the part of the MEDIS DAM focusing on the representation of 
MDs, modeled in two different perspectives. In the first one, detailed MD information 
is contained in the technical documents submitted by the notification proposer to obtain 
the approval of the CI start-up, as described in the box Evaluated MD. In the second 
one, each single investigational product used in real investigating conditions is 
represented by the role MD associated to the Entity Artifacts, as described in the box 
Tested MD. In this way it is possible to manage information gathered during the 
investigating process, for instance the identification of a specific MD involved in a 
precise adverse event. This splitting up creates an isomorphism in which the Roles 
related with the Entity Artifact are mirrored in the Entity Document. Similar conceptual 
differentiations have been adopted in the BRIDG model to distinguish the description 
of a “scheduled” clinical trial protocol from a “performed” one [3]. 
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Figure 2. MEDIS domain analysis model: Representation of an investigational product 
The Entity Document is associated with the Role MD description along with the 
description of the other elements related to the investigational product (Kit description, 
Component description, Drug description, Placebo description). Each of them has a 
specific Participation: the Role MD description participates to the whole CI process 
either as Investigated, Comparator or Kit part. The investigational product can be 
either a MD or a Kit, which is a composition of different MDs and/or Components. 
Moreover, MDs can incorporate a medicinal substance described in the Role Drug 
description. A CI can evaluate the safety and efficacy of an investigational MD 
comparing it with another MD, or with a drug or a placebo. In these cases these Roles 
participate as Comparator in the whole CI process. 
The Entity Artifact has the analogous Roles of those described in Evaluated MD, 
but it is associated with the Participation Deployed and the Act Investigating process. 
6. Conclusion and Future Work 
The paper describes the MEDIS DAM based on HL7 RIM. This standard has proved to 
be useful for the representation of CI lifecycle ranging from the notification sub-
process to the collection of the CI results. Its adoption represents a first step forward 
the development of a common standard language, which improves information sharing 
among different stakeholders. This is particularly important in a domain where 
standardization is at its initial stage. At the moment the notification module has been 
developed and is actually under a testing phase. The database design was based on our 
HL7 DAM, which makes it possible to easily change, upgrade and expand future 
interacting information systems. These features allow the different stakeholders to 
develop their own information system and eventually adapt it to changes due to new 
European regulation and/or local requirements.  
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